A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer

Trial Profile

A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs CAT 5001 (Primary) ; Cyclophosphamide; Pentostatin
  • Indications Lung cancer; Mesothelioma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2016 Planned End Date changed from 1 Apr 2018 to 1 Sep 2017.
    • 04 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Nov 2015 Protocol has been amended to include lung cancer, pancreatic cancer and maximum age limit in inclusion criteria, change treatment arms from 4 to 7 and add a primary endpoint of RP2D.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top